XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration and License Agreements - Astellas Pharma Inc - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Mar. 23, 2020
USD ($)
Target
Jan. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue       $ 236,657 $ 301,326 $ 255,460 $ 284,760
Astellas Pharma Inc.              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue       34,700      
Collaboration and License Agreement | Astellas Pharma Inc.              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Number of targets selected | Target 1            
Number of additional collaboration target | Target 3            
Upfront payment received $ 80,000            
Milestone payments received   $ 5,000 $ 5,000        
Deferred revenue       34,700 44,500    
Amount due from customer       $ 1,300 $ 1,000    
Collaboration and License Agreement | Astellas Pharma Inc. | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Number of targets | Target 4            
Right to expand the number of additional collaboration target | Target 5            
Contingent milestone payments receivable $ 1,600,000            
Collaboration and License Agreement | Astellas Pharma Inc. | Minimum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Right to expand the number of additional collaboration target | Target 3